Trump to visit Fed on Thursday amid Powell feud, renovation probe
Investing.com - H.C. Wainwright maintained its buy rating and $40 price target on Kura Oncology (NASDAQ:KURA) stock following the company’s virtual event discussing KOMET-007 trial results. The stock, currently trading at $6.06, has strong analyst support with a consensus "Strong Buy" rating. According to InvestingPro data, analyst targets range from $8 to $40, suggesting significant upside potential.
The event, held Wednesday, presented detailed findings of ziftomenib combined with standard 7+3 chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients. The data, originally showcased at the European Hematology Association 2025 meeting, demonstrated high rates of composite complete response and minimal residual disease negativity in both NPM1-mutated and KMT2A-rearranged patient populations. With a strong current ratio of 8.07 and more cash than debt on its balance sheet, Kura appears well-positioned to advance its clinical programs.
Safety data indicated that treatment-related adverse events occurring in at least 10% of patients—including febrile neutropenia, decreased platelet count, and anemia—were comparable to those typically seen with standard 7+3 chemotherapy alone, suggesting no additional toxicity from ziftomenib. The drug also did not delay neutrophil and platelet recovery in responding patients.
A Grade 3 case of differentiation syndrome in a KMT2A-rearranged patient was successfully managed, according to the company’s presentation. Key opinion leaders at the event emphasized the importance of achieving early minimal residual disease negativity in first-line patients, particularly those with NPM1 mutations, noting its correlation with longer overall survival.
H.C. Wainwright noted that the Phase 1a/b KOMET-007 results collected to date support ziftomenib’s potential to address unmet needs in newly diagnosed AML patients. Kura Oncology plans to initiate Phase 3 KOMET-017 studies in the second half of 2025. Want deeper insights? InvestingPro subscribers get access to 8 additional ProTips and comprehensive financial analysis, including detailed Fair Value estimates and health scores for Kura Oncology.
In other recent news, Kura Oncology has been in the spotlight due to its clinical trial results and regulatory developments. The company presented data from the KOMET-007 trial, which evaluated ziftomenib in combination with chemotherapy for first-line acute myeloid leukemia (AML). The trial showed a 92% complete remission composite rate and a 76% complete remission with minimal residual disease negativity, with a safety profile similar to standard treatments. Additionally, Kura Oncology announced that the FDA accepted its New Drug Application for ziftomenib in relapsed or refractory NPM1-mutated AML and granted it priority review, setting a Prescription Drug User Fee Act date for November 30, 2025. Analysts from H.C. Wainwright, Citizens JMP, Leerink Partners, and Cantor Fitzgerald have reiterated their positive ratings on Kura Oncology’s stock, citing the promising trial results and potential market opportunities. The company’s strong financial position, with a pro forma cash position of $703.2 million, further supports its ongoing clinical programs. Kura Oncology plans to initiate pivotal Phase 3 trials in newly diagnosed patients in the second half of 2025. The developments suggest a strategic focus on advancing ziftomenib’s profile in both monotherapy and combination treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.